CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Clinical Studies
Original article

Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

Read the original article

Published by GlobeNewswire Clinical Studies on September 29, 2026 12:05 PM

Read Original